A novel, out-of-pocket, cost-effectiveness analysis comparing a frontline niraparib-for-all to a biomarker-based strategy in patients with advanced ovarian cancer by Lim, Stephanie, MD, Moss, Haley, MD, MBA, Havrilesky, Laura, MD, O'Cearbhaill, Roisin, MD, Abu-Rustum, Nadeem, MD, Liang, Maggie, MD, Wright, Jason, MD, Aviki, Emeline, MD, MBA

Get full text

10-year survival in patients diagnosed with high-grade epithelial ovarian cancer: a new metric for a new millennium by Filippova, Olga, MD, MSc, FACOG, Straubhar, Alli, MD, Santiago, Nicole Lugo, MD, Zivanovic, Oliver, MD, Gardner, Ginger, MD, Tew, William, MD, O'Cearbhaill, Roisin, MD, Grisham, Rachel, MD, Sonoda, Yukio, MD, Roche, Kara Long, MD, Chi, Dennis, MD

Get full text

Efficacy of niraparib by timing of surgery and residual disease: a post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study by O'Cearbhaill, Roisin, MD, Pérez-Fidalgo, Jose Alejandro, MD PhD, Monk, Bradley, MD, FACS, FACOG, Tusquets, Ignasi, MD, McCormick, Colleen, MD, MPH, Fuentes, Jose, MD PhD, Moore, Richard, MD, Vulsteke, Christof, MD PhD, Shahin, Mark, MD, Forget, Frédéric, Bradley, William, MD, Hietanen, Sakari, MD, O'Malley, David, MD, Dørum, Anne, MD, Slomovitz, Brian, MD, Baumann, Klaus, MD, PhD, Selle, Frédéric, MD, Calvert, Paula, MD, Artioli, Grazia, MD, Levy, Tally, MD, Kumar, Aalok, MD, Malinowska, Izabela, MD, PhD, Li, Yong, PhD, Gupta, Divya, MD, González-Martín, Antonio, MD, PhD

Get full text

COVID-19 outcomes of patients with gynecologic cancer in New York City: an updated analysis by Lara, Olivia, MD, MS, Smith, Maria, Bachelor of Science, Wang, Yuyan, PhD, O'Cearbhaill, Roisin, MD, Blank, Stephanie, MD, Kolev, Valentin, MD, Carr, Caitlin, MD, Knisely, Anne, MD, McEachron, Jennifer, DO, Gabor, Lisa, MD, Frey, Melissa, MD, Jee, Justin, Fehniger, Julia, MD, Lee, Yi-Chun, MD, Isani, Sara, MD, Liu, Mengling, PHD, Wright, Jason, MD, Pothuri, Bhavana, MD, MS

Get full text

Postoperative morbidity after secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer: An exploratory analysis of a randomized phase II study evaluating hyp... by Praiss, Aaron, MD, Moukarzel, Lea, MD, Chi, Dennis, MD, Sonoda, Yukio, MD, Roche, Kara Long, MD, Gardner, Ginger, MD, Tew, William, MD, Grisham, Rachel, MD, O’Cearbhaill, Roisin, MD, Zivanovic, Oliver, MD

Get full text

Ten-year conditional probability of survival for patients with ovarian cancer: A new metric for the new millennium (480) by Kahn, Ryan, MD, MHS, Filippova, Olga, MD, MSc, FACOG, Straubhar, Alli, MD, An, Anjile, MPH, Zivanovic, Oliver, MD, Gardner, Ginger, MD, O’Cearbhaill, Roisin, MD, Tew, William, MD, Sonoda, Yukio, MD, Roche, Kara Long, MD, Chi, Dennis, MD

Get full text

Safety and immunogenicity of Anti PD-L1 (Atezolizumab) given as an immune primer or concurrently with extended field chemoradiotherapy for node positive locally advanced cervical c... by Mayadev, Jyoti, MD, Zamarin, Dmitriy, MD PhD, Deng, Wei, PhD, Lankes, Heather, PhD, MPH, Pesci, Giulio, Park, Kay, Banbury, Barbara, PhD, Sherry, Ned, Ghamande, Sharad, MD, Holman, Laura, MD, Mathews, Cara, MD, O’Cearbhaill, Roisin, MD, Aghajanian, Carol, MD, Schilder, Russell, MD

Get full text

Predicting outcomes in female germ cell patients using a modified International Germ Cell Cancer Collaborative Group classification system to guide management (100) by Manning-Geist, Beryl, MD, Deng, Luxue, MD, Knezevic, Andrea, MS, Bromberg, Maria, Funt, Samuel, MD, Zivanovic, Oliver, MD, Roche, Kara Long, MD, Sonoda, Yukio, MD, Gardner, Ginger, MD, Grisham, Rachel, MD, O’Cearbhaill, Roisin, MD, Abu-Rustum, Nadeem, MD, Chi, Dennis, MD, Aghajanian, Carol, MD, Feldman, Darren, MD, Liu, Ying, MD, MPH

Get full text